Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377561 | 0.92 | SMN1; SMN2 (0.57) | SMN1; SMN2NPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3379807 | 0.78 | PTGES (0.52) | SMN1; SMN2ALDH1A1LMNALPAR1LPAR5 | |
| SCHEMBL3377553 | 0.72 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3377212 | 0.72 | SMN1; SMN2 (0.71) | SMN1; SMN2NPSR1GAAHTTKEAP1 | |
| SCHEMBL18301543 | 0.70 | SMN1; SMN2 (0.61) | SMN1; SMN2NPSR1GAAHTTKEAP1 | |
| SCHEMBL3377557 | 0.67 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3377298 | 0.64 | PGR (0.50) | SMN1; SMN2CYP3A4CYP2C9MAPTLMNA | |
| SCHEMBL5342714 | 0.63 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAHTTKEAP1NFE2L2 | |
| SCHEMBL680618 | 0.63 | MAPK14 (0.54) | LMNALPAR1LPAR5MEN1KMT2A | |
| SCHEMBL11511159 | 0.62 | MAPT (0.60) | MAPTLMNALPAR1LPAR5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | SMN1; SMN2 1551/4885NPSR1 1508/4885CYP3A4 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.